Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology

Launched by RIGSHOSPITALET, DENMARK · Mar 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the health of mothers, their children, and the placenta in families who have used assisted reproductive technology (like IVF) compared to those who conceived naturally. The goal is to understand how these different ways of becoming pregnant affect things like heart health and growth during pregnancy, as well as the long-term health of the children. Researchers will look closely at the biology of the parents and children, including genetic patterns, to see how they might influence health outcomes.

To participate, pregnant women must have undergone fertility treatments at specific hospitals or be scheduled for prenatal ultrasounds there. However, certain women won't be included, such as those with severe pre-existing health conditions or those carrying more than one baby. If you choose to join, you can expect to provide information about your health and participate in assessments about your pregnancy and your child's development over time. This trial is a unique opportunity to contribute to important research that could help improve health for future generations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pregnant women who have either had fertility treatment at Rigshospitalet or Herlev Hospital (FET and fresh ET groups) or are scheduled for prenatal ultrasounds at Rigshospitalet or Herlev Hospital (NC group) will be screened for eligibility. Inclusion must happen before their routine ultrasound scan in 1. trimester.
• Exclusion Criteria:
• • Maternal pregestational diabetes type 1 or 2
• • Non-singleton pregnancies
• • Maternal pregestational BMI \> 35 kg/m2
• • Severe maternal co-morbidity
• • Oocyte donation